52.96
price down icon0.51%   -0.27
 
loading
前日終値:
$53.23
開ける:
$53.41
24時間の取引高:
8.32M
Relative Volume:
0.47
時価総額:
$179.54B
収益:
$45.45B
当期純損益:
$16.18B
株価収益率:
14.59
EPS:
3.6297
ネットキャッシュフロー:
$8.96B
1週間 パフォーマンス:
-2.59%
1か月 パフォーマンス:
-9.84%
6か月 パフォーマンス:
-15.44%
1年 パフォーマンス:
-53.51%
1日の値動き範囲:
Value
$52.93
$53.55
1週間の範囲:
Value
$52.38
$56.23
52週間の値動き範囲:
Value
$45.05
$114.19

Novo Nordisk Adr Stock (NVO) Company Profile

Name
名前
Novo Nordisk Adr
Name
セクター
Healthcare (1140)
Name
電話
-
Name
住所
-
Name
職員
78,387
Name
Twitter
@novonordisk
Name
次回の収益日
2024-12-06
Name
最新のSEC提出書
Name
NVO's Discussions on Twitter

NVO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
52.96 236.52B 45.45B 16.18B 8.96B 3.6297
Drug Manufacturers - General icon
LLY
Lilly Eli Co
825.45 736.03B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
190.40 463.72B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.99 403.22B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.36 254.84B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.49 217.76B 63.43B 16.42B 14.72B 6.4861

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-01 アップグレード HSBC Securities Hold → Buy
2025-09-29 ダウングレード Morgan Stanley Equal-Weight → Underweight
2025-09-17 アップグレード Berenberg Hold → Buy
2025-09-16 アップグレード Rothschild & Co Redburn Neutral → Buy
2025-09-09 アップグレード Bernstein Mkt Perform → Outperform
2025-08-13 アップグレード BNP Paribas Exane Underperform → Neutral
2025-08-05 ダウングレード UBS Buy → Neutral
2025-07-31 ダウングレード HSBC Securities Buy → Hold
2025-07-30 ダウングレード Barclays Overweight → Equal Weight
2025-04-17 ダウングレード BMO Capital Markets Outperform → Market Perform
2025-03-13 アップグレード Kepler Hold → Buy
2025-03-03 ダウングレード Stifel Buy → Hold
2025-02-12 開始されました Morgan Stanley Equal-Weight
2025-01-06 アップグレード Bernstein Underperform → Mkt Perform
2024-05-30 開始されました Goldman Buy
2024-04-12 開始されました BMO Capital Markets Outperform
2024-01-23 開始されました Morgan Stanley Overweight
2024-01-16 再開されました UBS Neutral
2023-12-01 開始されました Cantor Fitzgerald Overweight
2023-10-02 開始されました Argus Buy
2023-07-14 開始されました HSBC Securities Buy
2022-07-15 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-06-28 ダウングレード UBS Neutral → Sell
2022-06-27 アップグレード Exane BNP Paribas Underperform → Neutral
2022-06-07 アップグレード JP Morgan Neutral → Overweight
2022-05-31 アップグレード Guggenheim Neutral → Buy
2022-04-25 アップグレード Cowen Market Perform → Outperform
2022-04-12 アップグレード Morgan Stanley Underweight → Equal-Weight
2022-03-16 アップグレード Deutsche Bank Hold → Buy
2022-01-25 ダウングレード Liberum Hold → Sell
2021-12-20 ダウングレード JP Morgan Overweight → Neutral
2021-12-17 ダウングレード Deutsche Bank Buy → Hold
2021-01-20 ダウングレード Credit Suisse Outperform → Neutral
2021-01-15 開始されました Deutsche Bank Buy
2020-09-29 開始されました Berenberg Hold
2020-07-06 ダウングレード BofA Securities Buy → Neutral
2020-05-11 ダウングレード UBS Buy → Neutral
2020-05-04 開始されました Cowen Market Perform
2020-03-16 アップグレード BofA/Merrill Neutral → Buy
2020-01-03 ダウングレード Guggenheim Buy → Neutral
2019-11-18 アップグレード Barclays Equal Weight → Overweight
2019-09-17 アップグレード Citigroup Neutral → Buy
2019-08-30 ダウングレード Jefferies Hold → Underperform
2019-06-20 ダウングレード Deutsche Bank Buy → Hold
2019-06-11 アップグレード Barclays Underweight → Equal Weight
2019-04-29 アップグレード Credit Suisse Neutral → Outperform
2019-01-29 開始されました Exane BNP Paribas Outperform
2018-12-11 再開されました Jefferies Hold
2018-10-09 開始されました Guggenheim Buy
2017-12-29 アップグレード JP Morgan Underweight → Neutral
2017-12-06 アップグレード BofA/Merrill Neutral → Buy
2017-12-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2017-09-25 ダウングレード Exane BNP Paribas Outperform → Neutral
2017-09-06 アップグレード BofA/Merrill Underperform → Neutral
すべてを表示

Novo Nordisk Adr (NVO) 最新ニュース

pulisher
Oct 23, 2025

Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership - Benzinga

Oct 23, 2025
pulisher
Oct 22, 2025

Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail

Oct 22, 2025
pulisher
Oct 22, 2025

Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail

Oct 22, 2025
pulisher
Oct 18, 2025

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Oct 18, 2025
pulisher
Oct 16, 2025

What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm

Oct 16, 2025
pulisher
Oct 16, 2025

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Sahm

Oct 16, 2025
pulisher
Oct 15, 2025

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Sahm

Oct 15, 2025
pulisher
Oct 13, 2025

ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView

Oct 13, 2025
pulisher
Oct 11, 2025

Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm

Oct 11, 2025
pulisher
Oct 11, 2025

Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail

Oct 11, 2025
pulisher
Oct 09, 2025

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm

Oct 09, 2025
pulisher
Oct 04, 2025

UBS Sticks to Their Hold Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 04, 2025
pulisher
Oct 02, 2025

BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail

Oct 02, 2025
pulisher
Oct 01, 2025

J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 01, 2025
pulisher
Sep 30, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - sharewise.com

Sep 30, 2025
pulisher
Sep 30, 2025

Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Sep 30, 2025
pulisher
Sep 28, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa

Sep 28, 2025
pulisher
Sep 27, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India

Sep 27, 2025
pulisher
Sep 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent

Sep 24, 2025
pulisher
Sep 24, 2025

NVO Stock Quote Price and Forecast - CNN

Sep 24, 2025
pulisher
Sep 23, 2025

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 23, 2025
pulisher
Sep 20, 2025

NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 20, 2025
pulisher
Sep 19, 2025

Tools to assess Novo Nordisk A s (b Shares) Adrhedged’s risk profileJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Sep 19, 2025
pulisher
Sep 18, 2025

Novo Nordisk And Prudential Stand Out In European ADR Gains - Finimize

Sep 18, 2025
pulisher
Sep 18, 2025

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Sahm

Sep 18, 2025
pulisher
Sep 18, 2025

Custom strategy builders for tracking Novo Nordisk A s (b Shares) AdrhedgedStock Surge & AI Forecasted Entry/Exit Points - newser.com

Sep 18, 2025

Novo Nordisk Adr (NVO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$291.76
price down icon 0.39%
$120.94
price up icon 0.17%
drug_manufacturers_general PFE
$24.76
price up icon 0.36%
drug_manufacturers_general MRK
$87.49
price up icon 0.36%
drug_manufacturers_general SNY
$51.64
price up icon 4.28%
大文字化:     |  ボリューム (24 時間):